References
- Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz M K, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489–2495
- Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96: 410–419
- Cavalli F, Isaacson P G, Gascoyne R D, Zucca E. MALT Lymphomas. Hematology Am Soc Hematol Educ Program 2001; 241–258
- Hitchcock S, Ng A K, Fisher D C, Silver B, Bernardo M P, Dorfman D M, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2002; 52: 1058–1066
- Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624–1630
- Raderer M, Jager G, Brugger S, Puspok A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003; 65: 306–310
- Martinelli G, Laszlo D, Ferreri A J, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979–1983
- Raderer M, Wohrer S, Streubel B, Drach J, Jager U, Turetschek K, et al. Activity of Rituximab plus Cyclophosphamide, Doxorubicin/Mitoxantrone, Vincristine and Prednisone in patients with relapsed MALT lymphoma. Oncology 2006; 70: 411–417
- Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
- Corazzelli G, Russo F, Villani O, Vassallo P, Pinto A. Cladribine(2-CDA) plus sequential rituximab in newly diagnosed disseminated extranodal marzinal zone B-cell lymphoma. A phase II study. Blood (Suppl.) 2006; 108: 781a